Xenon Pharmaceuticals (XENE)
Xenon Pharmaceuticals on one page: short interest, daily short volume, fails to deliver, planned sales, large holders, 13F holders, financials, earnings dates and insider trades. Listed on Nasdaq, classified by the SEC as pharmaceutical preparations.
6.0M
Short interest
settlement 2026-09-30
1.6
Days to cover
-10.6 days vs prior
44.9%
Short share of volume
2026-10-09
671
Fails to deliver
settlement 2026-09-01
Mon 2 Nov
Next earnings
estimated date
2 people
Insiders buying, 30 days
$1.7M combined, latest 2026-09-30
$615K
Insider flow, 90 days
2 buys, 3 sells
As of 2026-10-09.
Short interest
FINRA, twice a month. The newest 24 settlements in the table, 48 in the chart. JSONAs of 30 September 2026, short interest in XENE is 6,041,487 shares, down 302,648 shares over the last month. Over the last 48 readings it ranged from 2,878,735 shares (29 November 2024) to 7,705,812 shares (30 September 2025). At the reported average volume of 3.8M shares a day that is 1.6 days to cover.
Embed this chart.The embed keeps its attribution line.
<iframe src="https://xoomar.com/embed/stocks/xene" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>
| Settlement | Shares short | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|
| 2026-09-30 | 6,041,487 | -6.3% | 3,834,835 | 1.58 |
| 2026-09-15 | 6,444,815 | +1.6% | 527,345 | 12.22 |
| 2026-08-31 | 6,344,135 | +11.9% | 698,275 | 9.09 |
| 2026-08-14 | 5,668,994 | +5.3% | 618,635 | 9.16 |
| 2026-07-31 | 5,384,476 | -15.0% | 734,532 | 7.33 |
| 2026-07-15 | 6,337,096 | +1.3% | 1,778,010 | 3.56 |
| 2026-06-30 | 6,257,737 | +42.0% | 2,112,290 | 2.96 |
| 2026-06-15 | 4,408,157 | +9.0% | 1,376,477 | 3.20 |
| 2026-05-29 | 4,044,948 | +5.5% | 1,377,667 | 2.94 |
| 2026-05-15 | 3,833,400 | -7.6% | 947,846 | 4.04 |
| 2026-04-30 | 4,149,067 | -14.5% | 898,777 | 4.62 |
| 2026-04-15 | 4,854,352 | +0.1% | 902,450 | 5.38 |
| 2026-03-31 | 4,851,044 | -11.0% | 1,368,500 | 3.54 |
| 2026-03-13 | 5,451,476 | -1.5% | 3,210,098 | 1.70 |
| 2026-02-27 | 5,533,096 | +2.9% | 816,874 | 6.77 |
| 2026-02-13 | 5,379,792 | -2.9% | 728,885 | 7.38 |
| 2026-01-30 | 5,541,753 | +3.2% | 844,032 | 6.57 |
| 2026-01-15 | 5,371,266 | -9.4% | 1,232,230 | 4.36 |
| 2025-12-31 | 5,927,441 | +3.6% | 719,882 | 8.23 |
| 2025-12-15 | 5,720,672 | -2.9% | 803,381 | 7.12 |
| 2025-11-28 | 5,889,334 | -2.5% | 800,250 | 7.36 |
| 2025-11-14 | 6,043,619 | +4.5% | 819,858 | 7.37 |
| 2025-10-31 | 5,785,686 | -5.9% | 792,372 | 7.30 |
| 2025-10-15 | 6,148,669 | -20.2% | 759,555 | 8.10 |
Daily short volume
FINRA Reg SHO, the last 30 sessions. JSONAs of 9 October 2026, the short share of XENE volume is 44.9%, down 3.1 points over the last five sessions. Over the last 30 readings it ranged from 26.2% (21 September 2026) to 80.8% (11 September 2026). The latest reading is 8.8 points below the 30-session average of 53.7%, on 374K shares reported.
| Date | Short volume | Total volume | Short share | Exempt |
|---|---|---|---|---|
| 2026-10-09 | 168K | 374K | 44.9% | 0 |
| 2026-10-08 | 469K | 908K | 51.7% | 0 |
| 2026-10-07 | 364K | 761K | 47.9% | 0 |
| 2026-10-06 | 639K | 1.2M | 52.8% | 0 |
| 2026-10-05 | 390K | 696K | 56.0% | 407 |
| 2026-10-02 | 389K | 811K | 47.9% | 711 |
| 2026-10-01 | 893K | 1.6M | 55.3% | 376 |
| 2026-09-30 | 344K | 1.1M | 30.6% | 0 |
| 2026-09-29 | 770K | 1.5M | 50.6% | 0 |
| 2026-09-28 | 433K | 1.1M | 40.0% | 27,541 |
| 2026-09-25 | 595K | 1.2M | 49.5% | 38 |
| 2026-09-24 | 736K | 1.7M | 44.3% | 0 |
| 2026-09-23 | 573K | 1.7M | 34.6% | 0 |
| 2026-09-22 | 530K | 960K | 55.2% | 9,350 |
| 2026-09-21 | 425K | 1.6M | 26.2% | 10,497 |
| 2026-09-18 | 4.2M | 9.5M | 44.1% | 306,647 |
| 2026-09-17 | 328K | 443K | 74.1% | 0 |
| 2026-09-16 | 168K | 325K | 51.7% | 220 |
| 2026-09-15 | 128K | 234K | 54.8% | 46 |
| 2026-09-14 | 77K | 136K | 56.5% | 229 |
| 2026-09-11 | 154K | 190K | 80.8% | 0 |
| 2026-09-10 | 172K | 333K | 51.5% | 400 |
| 2026-09-09 | 86K | 157K | 54.5% | 0 |
| 2026-09-08 | 130K | 264K | 49.2% | 0 |
| 2026-09-04 | 102K | 142K | 71.6% | 0 |
| 2026-09-03 | 79K | 121K | 65.0% | 0 |
| 2026-09-02 | 169K | 272K | 62.4% | 0 |
| 2026-09-01 | 99K | 157K | 63.2% | 43 |
| 2026-08-31 | 186K | 298K | 62.5% | 0 |
| 2026-08-28 | 190K | 235K | 80.7% | 0 |
Fails to deliver
SEC, the last 30 settlement dates with a fail. JSONAs of 1 September 2026, the fails-to-deliver balance in XENE is 671 shares, up 655 shares over the last settlement date. Over the last 30 readings it ranged from 1 share (29 July 2026) to 60,116 shares (26 June 2026). The latest reading sits at the bottom of that range.
| Settlement | Shares failed | Price | Value |
|---|---|---|---|
| 2026-09-01 | 671 | $60.22 | $40K |
| 2026-08-24 | 16 | $60.77 | $972 |
| 2026-08-13 | 16 | $65.26 | $1K |
| 2026-08-03 | 25 | $62.67 | $2K |
| 2026-07-31 | 322 | $64.19 | $21K |
| 2026-07-29 | 1 | $64.94 | $65 |
| 2026-07-28 | 3,116 | $65.78 | $205K |
| 2026-07-27 | 3,651 | $65.42 | $239K |
| 2026-07-20 | 7 | $68.26 | $478 |
| 2026-07-16 | 17 | $67.71 | $1K |
| 2026-07-14 | 9,120 | $67.72 | $618K |
| 2026-07-09 | 7,660 | $69.95 | $536K |
| 2026-07-08 | 582 | $63.37 | $37K |
| 2026-06-26 | 60,116 | $56.78 | $3.4M |
| 2026-06-23 | 59 | $54.79 | $3K |
| 2026-06-08 | 1,075 | $51.73 | $56K |
| 2026-05-26 | 161 | $54.17 | $9K |
| 2026-05-21 | 89 | $54.68 | $5K |
| 2026-05-18 | 90 | $54.39 | $5K |
| 2026-04-21 | 113 | $57.09 | $6K |
| 2026-04-20 | 4,206 | $59.70 | $251K |
| 2026-04-06 | 325 | $56.85 | $18K |
| 2026-03-26 | 1,140 | $55.57 | $63K |
| 2026-03-24 | 65 | $54.42 | $4K |
| 2026-03-11 | 3,451 | $60.61 | $209K |
| 2026-03-10 | 48,878 | $62.76 | $3.1M |
| 2026-03-06 | 670 | $42.05 | $28K |
| 2026-02-27 | 5,406 | $44.92 | $243K |
| 2026-02-25 | 27,129 | $44.79 | $1.2M |
| 2026-02-20 | 4,549 | $43.08 | $196K |
Insider trades
SEC Form 4, newest first, 50 of 100 shown. JSONOver the last 90 days XENE insiders reported 2 open-market buys ($1.7M) against 3 sells ($1.1M), so the dollar flow leans toward buying. Latest filing: MORTIMER IAN (PRESIDENT & CEO) on 2026-09-30.
| Date | Insider | Title | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|---|
| 2026-09-30 | MORTIMER IAN | PRESIDENT & CEO | Buy | 30K | $37.38 | $1.1M | 50K |
| 2026-09-30 | Kelly Thomas Patrick | Chief Financial Officer | Buy | 15K | $37.32 | $560K | 15K |
| 2026-09-01 | Svoronos Dawn | Director | Option exercise | 5K | $8.15 | $42K | 31K |
| 2026-08-28 | KENNEY CHRISTOPHER JOHN | Chief Medical Officer | Sell | 700 | $60.98 | $43K | 2 |
| 2026-08-28 | KENNEY CHRISTOPHER JOHN | Chief Medical Officer | Sell | 6K | $60.17 | $383K | 702 |
| 2026-08-11 | GANNON STEVEN | Director | Sell | 10K | $64.06 | $641K | 2K |
| 2026-06-05 | PATOU GARY | Director | Sell | 1K | $53.14 | $70K | 25K |
| 2026-06-05 | Cannon Gillian | Director | Sell | 1K | $53.14 | $63K | 1K |
| 2026-06-01 | Svoronos Dawn | Director | Tax withholding | 1K | $53.41 | $76K | 26K |
| 2026-06-01 | Svoronos Dawn | Director | Option exercise | 3K | price not stated in the filing | not stated | 28K |
| 2026-06-01 | Cannon Gillian | Director | Option exercise | 3K | price not stated in the filing | not stated | 3K |
| 2026-06-01 | GANNON STEVEN | Director | Option exercise | 3K | price not stated in the filing | not stated | 13K |
| 2026-06-01 | GANNON STEVEN | Director | Tax withholding | 1K | $53.41 | $76K | 12K |
| 2026-06-01 | GAROFALO ELIZABETH A. | Director | Option exercise | 3K | price not stated in the filing | not stated | 3K |
| 2026-06-01 | Gover Justin D. | Director | Option exercise | 3K | price not stated in the filing | not stated | 3K |
| 2026-06-01 | Machado Patrick | Director | Option exercise | 3K | price not stated in the filing | not stated | 3K |
| 2026-06-01 | PATOU GARY | Director | Option exercise | 3K | price not stated in the filing | not stated | 26K |
| 2026-05-12 | GANNON STEVEN | Director | Option exercise | 4K | $7.38 | $26K | 11K |
| 2026-03-13 | MORTIMER IAN | PRESIDENT & CEO | Sell | 7K | $55.23 | $404K | 20K |
| 2026-03-13 | DiFabio Andrea | Chief Legal Officer | Sell | 1K | $55.23 | $74K | 7K |
| 2026-03-13 | KENNEY CHRISTOPHER JOHN | Chief Medical Officer | Sell | 1K | $55.23 | $78K | 7K |
| 2026-03-12 | MORTIMER IAN | PRESIDENT & CEO | Option exercise | 13K | price not stated in the filing | not stated | 27K |
| 2026-03-12 | DiFabio Andrea | Chief Legal Officer | Option exercise | 4K | price not stated in the filing | not stated | 9K |
| 2026-03-12 | KENNEY CHRISTOPHER JOHN | Chief Medical Officer | Option exercise | 4K | price not stated in the filing | not stated | 8K |
| 2026-03-10 | MORTIMER IAN | PRESIDENT & CEO | Sell | 11K | $60.11 | $677K | 15K |
| 2026-03-10 | DiFabio Andrea | Chief Legal Officer | Sell | 3K | $60.11 | $157K | 5K |
| 2026-03-10 | KENNEY CHRISTOPHER JOHN | Chief Medical Officer | Sell | 3K | $60.11 | $167K | 5K |
| 2026-03-09 | MORTIMER IAN | PRESIDENT & CEO | Option exercise | 20K | price not stated in the filing | not stated | 26K |
| 2026-03-09 | DiFabio Andrea | Chief Legal Officer | Option exercise | 8K | price not stated in the filing | not stated | 8K |
| 2026-03-09 | KENNEY CHRISTOPHER JOHN | Chief Medical Officer | Option exercise | 8K | price not stated in the filing | not stated | 8K |
| 2026-03-09 | MORTIMER IAN | PRESIDENT & CEO | Sell | 65K | $62.06 | $4.0M | 6K |
| 2026-03-09 | MORTIMER IAN | PRESIDENT & CEO | Option exercise | 65K | $9.44 | $614K | 71K |
| 2026-03-09 | MORTIMER IAN | PRESIDENT & CEO | Sell | 62K | $60.08 | $3.7M | 6K |
| 2026-03-09 | MORTIMER IAN | PRESIDENT & CEO | Sell | 43K | $59.26 | $2.6M | 73K |
| 2026-03-09 | MORTIMER IAN | PRESIDENT & CEO | Option exercise | 105K | $4.75 | $499K | 111K |
| 2026-03-09 | MORTIMER IAN | PRESIDENT & CEO | Sell | 2K | $61.26 | $150K | 6K |
| 2026-03-09 | MORTIMER IAN | PRESIDENT & CEO | Sell | 10K | $60.47 | $609K | 8K |
| 2026-03-09 | MORTIMER IAN | PRESIDENT & CEO | Sell | 12K | $59.50 | $743K | 19K |
| 2026-03-09 | MORTIMER IAN | PRESIDENT & CEO | Option exercise | 25K | $3.10 | $78K | 31K |
| 2026-03-09 | MORTIMER IAN | PRESIDENT & CEO | Sell | 22K | $60.49 | $1.3M | 6K |
| 2026-03-09 | MORTIMER IAN | PRESIDENT & CEO | Sell | 32K | $59.88 | $1.9M | 28K |
| 2026-03-09 | MORTIMER IAN | PRESIDENT & CEO | Sell | 22K | $58.81 | $1.3M | 59K |
| 2026-03-09 | MORTIMER IAN | PRESIDENT & CEO | Option exercise | 75K | $8.40 | $630K | 81K |
| 2026-01-02 | MORTIMER IAN | PRESIDENT & CEO | Sell | 2K | $44.93 | $93K | 6K |
| 2026-01-02 | MORTIMER IAN | PRESIDENT & CEO | Sell | 38K | $44.40 | $1.7M | 8K |
| 2026-01-02 | MORTIMER IAN | PRESIDENT & CEO | Option exercise | 40K | $7.49 | $300K | 46K |
| 2025-12-08 | MORTIMER IAN | PRESIDENT & CEO | Sell | 2K | $46.32 | $93K | 6K |
| 2025-12-08 | MORTIMER IAN | PRESIDENT & CEO | Sell | 9K | $45.59 | $402K | 8K |
| 2025-12-05 | MORTIMER IAN | PRESIDENT & CEO | Sell | 14K | $45.03 | $647K | 17K |
| 2025-11-28 | MORTIMER IAN | PRESIDENT & CEO | Sell | 97 | $45.01 | $4K | 31K |
Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are rarer.
Planned sales (Form 144)
Newest first. JSON17 Form 144 notices on file for XENE worth $23.1M at the prices reported; 2 in the last 90 days worth $1.1M. Latest: CHRISTOPHER KENNEY filed on 2026-08-28 to sell 7,068 shares ($438K) from 2026-08-28.
| Filed | Seller | Shares | Market value | Of outstanding | Sale from | Broker |
|---|---|---|---|---|---|---|
| 2026-08-28 | CHRISTOPHER KENNEYOfficer | 7K | $438K | 0.007% | 2026-08-28 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-08-13 | STEVEN GANNONDirector | 10K | $641K | 0.010% | 2026-08-11 | RBC Wealth Management |
| 2026-06-05 | GARY PATOUDirector | 1K | $70K | 0.001% | 2026-06-05 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-06-05 | GILLIAN CANNONDirector | 1K | $63K | 0.001% | 2026-06-05 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-03-13 | IAN MORTIMEROfficer, Director | 7K | $404K | 0.009% | 2026-03-13 | Morgan Stanley Wealth Management Canada Inc. |
| 2026-03-13 | CHRISTOPHER JOHN KENNEYOfficer | 1K | $78K | 0.002% | 2026-03-13 | Morgan Stanley Wealth Management Canada Inc. |
| 2026-03-13 | ANDREA DIFABIOOfficer | 1K | $74K | 0.002% | 2026-03-13 | Morgan Stanley Wealth Management Canada Inc. |
| 2026-03-10 | IAN MORTIMEROfficer, Director | 11K | $677K | 0.014% | 2026-03-10 | Morgan Stanley Wealth Management Canada Inc. |
| 2026-03-10 | CHRISTOPHER JOHN KENNEYOfficer | 3K | $167K | 0.003% | 2026-03-10 | Morgan Stanley Wealth Management Canada Inc. |
| 2026-03-10 | ANDREA DIFABIOOfficer | 3K | $157K | 0.003% | 2026-03-10 | Morgan Stanley Wealth Management Canada Inc. |
| 2026-03-09 | IAN MORTIMEROfficer, Director | 270K | $16.3M | 0.325% | 2026-03-09 | Canaccord Genuity Corp. |
| 2026-01-02 | IAN MORTIMEROfficer, Director | 40K | $1.8M | 0.052% | 2026-01-02 | Canaccord Genuity Corp. |
| 2025-12-08 | IAN MORTIMEROfficer, Director | 11K | $495K | 0.014% | 2025-12-08 | Canaccord Genuity Corp. |
| 2025-12-05 | IAN MORTIMEROfficer, Director | 14K | $647K | 0.019% | 2025-12-05 | Canaccord Genuity Corp. |
| 2025-12-01 | IAN MORTIMEROfficer, Director | 97 | $4K | 0.000% | 2025-11-28 | Canaccord Genuity Corp. |
| 2025-10-01 | IAN MORTIMEROfficer, Director | 25K | $1.0M | 0.032% | 2025-10-01 | Canaccord Genuity Corp. |
| 2025-09-19 | SHERRY AULINFormer officer | 3K | $94K | 0.003% | 2025-09-19 | Morgan Stanley Wealth Management Canada Inc. |
Large holders (13D and 13G)
One row per reporting person with its latest filing, newest first. JSON5 holders report 5% or more of XENE in their latest filing, all on Schedule 13G (passive). The largest reported stake is Abigail P. Johnson at 10.3% of the class (9,959,795 shares), filed 2026-08-07 for an event on 2026-07-31.
| Filed | Form | Holder | Shares | Of class | Event |
|---|---|---|---|---|---|
| 2026-08-13 | 13G/Ano. 1 | Wellington Group Holdings LLPparent holding company | 1.4M | 1.5% | 2026-06-30 |
| 2026-08-13 | 13G/Ano. 1 | Wellington Management Group LLPparent holding company | 1.4M | 1.5% | 2026-06-30 |
| 2026-08-13 | 13G/Ano. 1 | Wellington Investment Advisors Holdings LLPparent holding company | 1.4M | 1.5% | 2026-06-30 |
| 2026-08-07 | 13G/Ano. 8 | Abigail P. Johnsonindividual | 10.0M | 10.3% | 2026-07-31 |
| 2026-08-07 | 13G/Ano. 8 | FMR LLCparent holding company | 10.0M | 10.3% | 2026-07-31 |
| 2026-05-15 | 13G/Ano. 1 | JANUS HENDERSON GROUP PLCparent holding company | 4.2M | 4.5% | 2026-03-31 |
| 2026-05-15 | 13G/Ano. 5 | Behzad Aghazadehparent holding company, individual | 5.8M | 6.3% | 2026-03-31 |
| 2026-05-15 | 13G/Ano. 5 | Avoro Capital Advisors LLCinvestment adviser, other entity | 5.8M | 6.3% | 2026-03-31 |
| 2026-05-15 | 13G/Ano. 3 | DRIEHAUS CAPITAL MANAGEMENT LLCinvestment adviser | 4.5M | 4.9% | 2025-12-31 |
| 2026-02-10 | 13G | Wellington Management Company LLPinvestment adviser | 4.8M | 6.0% | 2025-12-31 |
13F holders
Tracked managers holding XENE at their latest 13F. JSON8 of the 30 tracked managers held XENE at their latest 13F, $254.0M in total at quarter-end prices. Two Sigma Investments is the largest at $99.2M (0.1% of its portfolio) as of 2026-06-30. Over the prior quarter 4 added shares and 3 cut.
| Fund | Quarter | Shares | Value | Of portfolio | Change in shares |
|---|---|---|---|---|---|
| Two Sigma Investments | 2026-06-30 | 1.6M | $99.2M | 0.07% | +1.0M |
| Citadel Advisors | 2026-06-30 | 1.4M | $84.6M | 0.01% | -1.3M |
| Millennium Management | 2026-06-30 | 377K | $22.7M | 0.01% | +175K |
| Duquesne Family Office | 2026-06-30 | 239K | $14.4M | 0.28% | 0 |
| D. E. Shaw & Co. | 2026-06-30 | 224K | $13.5M | 0.01% | +205K |
| Renaissance Technologies | 2026-06-30 | 187K | $11.3M | 0.02% | -113K |
| Point72 Asset Management | 2026-06-30 | 130K | $7.9M | 0.01% | new |
| AQR Capital Management | 2026-06-30 | 7K | $438K | 0.00% | -16 |
Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.
Financials
SEC XBRL, as filed. JSONIn FY 2025 it generated -$279.1M of operating cash flow.
- Cash
- $119.5M
- Equity
- $1.24B
- Total assets
- $1.30B
- Shares outstanding
- 96,840,432
Quarterly, last 8 quarters
| Quarter | Period end | Revenue | Net income | Margin | Diluted EPS |
|---|---|---|---|---|---|
| Q2 FY 2026 | 2026-06-30 | n/a | -$110.7M | n/a | -1.11 |
| Q1 FY 2026 | 2026-03-31 | n/a | -$102.3M | n/a | -1.17 |
| Q4 FY 2025derived | 2025-12-31 | n/a | -$105.3M | n/a | n/a |
| Q3 FY 2025 | 2025-09-30 | n/a | -$90.9M | n/a | -1.15 |
| Q2 FY 2025 | 2025-06-30 | n/a | -$84.7M | n/a | -1.07 |
| Q1 FY 2025 | 2025-03-31 | n/a | -$65.0M | n/a | -0.83 |
| Q4 FY 2024derived | 2024-12-31 | n/a | -$65.7M | n/a | n/a |
| Q3 FY 2024 | 2024-09-30 | n/a | -$62.8M | n/a | -0.81 |
Fiscal years, with buybacks and dividends
| Fiscal year | Ends | Revenue | Net income | Operating cash flow | Capex | Buybacks | Dividends |
|---|---|---|---|---|---|---|---|
| FY 2025 | 2025-12-31 | n/a | -$345.9M | -$279.1M | $799K | n/a | n/a |
| FY 2024 | 2024-12-31 | n/a | -$234.3M | -$181.4M | $3.1M | n/a | n/a |
| FY 2023 | 2023-12-31 | n/a | -$182.4M | -$151.1M | $5.6M | n/a | n/a |
| FY 2022 | 2022-12-31 | n/a | -$125.4M | -$101.0M | $2.9M | n/a | n/a |
| FY 2021 | 2021-12-31 | n/a | -$78.9M | -$69.5M | $2.0M | n/a | n/a |
Quarters are the three-month figures the company reports; a fourth quarter marked derived is the fiscal year less the three reported quarters, since companies report it only inside the 10-K. Fiscal years are the annual figures. Buybacks are the cash the company paid to repurchase its common stock in the year, not the amount authorized. Balance sheet lines are as of 2026-06-30; shares outstanding as of 2026-08-03 from the cover page.
What this page is
Xenon Pharmaceuticals in the regulatory record
Regulators publish company data in separate files that never sit next to each other: FINRA's twice-monthly short interest, its daily short sale volume, the SEC's fails-to-deliver counts, and each insider's Form 4. A company page puts those series for one ticker on one URL, with planned sales, large holders, 13F holders and financials beside them, so the short position, the daily flow, the settlement fails and what insiders are doing can be read together.
Each section has its own history table, a one-line summary of the latest figures and its own JSON and CSV links, and says when its source last updated.
This page follows Xenon Pharmaceuticals (XENE), SEC CIK 1582313, listed on Nasdaq, classified by the SEC as pharmaceutical preparations. The cross-market tables live on the short interest and insider transactions hubs.
Source and updates
- Short interest
- FINRA consolidated short interestSource: FINRA.Twice a month, about eight business days after settlement. Latest 2026-09-30.JSON and CSV
- Daily short volume
- FINRA Reg SHO daily filesSource: FINRA.Every trading day, the morning after FINRA posts it. Latest 2026-10-09.JSON and CSV
- Fails to deliver
- SEC fails-to-deliver dataSource: SEC.Twice a month, a few weeks after the half month ends. Latest 2026-09-01.JSON and CSV
- Planned sales
- SEC EDGAR Form 144Source: SEC.New notices appear shortly after the SEC posts them; a notice is filed on or before the sale. Latest 2026-08-28.JSON and CSV
- Large holders
- SEC EDGAR Schedule 13D and 13GSource: SEC.New filings appear shortly after the SEC posts them. A 13D is due within five business days of crossing 5%; a 13G follows the passive schedule. Latest 2026-08-13.JSON and CSV
- 13F holders
- SEC EDGAR Form 13F-HRSource: SEC.Quarterly, filed within 45 days of quarter end; 30 tracked managers. Latest 2026-06-30.JSON and CSV
- Financials
- SEC EDGAR 10-K and 10-Q filingsSource: SEC.Weekly; values are as filed in the 10-Q and 10-K. Latest 2026-06-30.JSON and CSV
- Earnings dates
- SEC EDGAR 8-K filings (Item 2.02)Source: SEC.Twice a day. Reported dates come from the company's 8-K filings; the next date is marked as an estimate until the 8-K arrives. Latest 2026-08-06.JSON and CSV
- Insider trades
- SEC EDGAR Form 4Source: SEC.New filings appear shortly after the SEC posts them; they're due two business days after the trade. Latest 2026-09-30.JSON and CSV
- Company record
- EDGAR filing index for CIK 1582313Ticker, name and exchange from the SEC's company list, refreshed weekly.
- Rate limits
- 10 requests a minute without a key, 30 with a free key from a free account.
How to read it
- Read the position against the flow: rising short interest with a high daily short share is new shorting; rising short interest with a normal short share is old shorts holding on.
- Insider buys next to a large short position are rare and stand out; insider sells next to one are common and mean little.
- Fails to deliver matter relative to the float, not in absolute shares; a million failed shares in a mega cap is noise.
Analysis of what the data shows, not advice. XOOMAR does not recommend buying, selling or holding anything.
Other companies the SEC classifies as pharmaceutical preparations
- UTHRUnited Therapeutics
- CPIXCumberland Pharmaceuticals
- REGNRegeneron Pharmaceuticals
- LLYEli Lilly
- VRTXVertex Pharmaceuticals
- ALNYAlnylam Pharmaceuticals
- CYTKCytokinetics
- BMYBristol Myers Squibb
- PTCTPTC Therapeutics
- INSMInsmed
- MDGLMadrigal Pharmaceuticals
- CORTCorcept Therapeutics
- IONSIonis Pharmaceuticals
- SDGRSchrodinger
- ROIVRoivant Sciences
- JNJJohnson & Johnson
- OPKOpko Health
- ALKSAlkermes
- ABBVAbbVie
- ABTAbbott Laboratories
- KNSAKiniksa Pharmaceuticals International
- BBIOBridgeBio Pharma
- ZTSZoetis
- JAZZJazz Pharmaceuticals
Datasets
Frequently Asked Questions
How much of XENE is sold short?
What is XENE's daily short volume?
Does XENE have fails to deliver?
Are XENE insiders buying or selling?
Have XENE insiders filed to sell?
Who owns 5% or more of XENE?
What did XENE report last quarter?
Which tracked 13F managers own XENE?
Data on this page is provided for informational purposes only and is not financial advice. See our editorial policy.